Paul J.

I, Paul J. Atkins, nominated by the United States of America and residing in the United States, a Member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I recently retired as Vice President at Oriel Therapeutics Inc (a Novartis company) and have established a consulting Company (Inhaled Delivery Solutions) that provides technical/regulatory guidance on the development of inhaled medicines. I am also Executive Chairman of a biotec start company (Nob Hill Therapeutics) which is developing a novel dry powder nebulizer.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines. I understand that this written agreement is a condition of my service.
4. My interests, and those of my personal partner, include the following -
   1. Proprietary interests: None
   2. Financial interests: Shares in Novartis and my spouse owns shares in her former employer (GSK, a manufacturer of inhaled medicines)
   3. Employment, consultancy, directorship or other positions:  No current consulting interests
   4. Government advice and other policy development: None
   5. Paid research activities, fellowships or grants: None
   6. Other interests: N/A
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is my personal funds
6. Pursuant to paragraph 11 of the COI Guidelines I declare that I have declined to disclose information falling within paragraph 10 of those Guidelines and I undertake to ensure that I am completely excluded from discussions and decisions on topics related to the information that I have declined to disclose.
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Paul J. Atkins PhD.
16th April 2021